Bayer Battles Generic Yasmin Hopeful In Fed. Circ.

Law360, Washington (December 7, 2011, 4:54 PM EST) -- Bayer Healthcare Pharmaceuticals Inc. sought to persuade the Federal Circuit on Wednesday that it has a valid case to block generics makers from introducing a version of its oral contraceptive Yasmin, saying its patent covers all uses of the drug.

In September 2010, a New York federal judge ruled in favor of Watson Laboratories Inc. and Sandoz Inc. in Bayer's Hatch-Waxman Act suit, saying the disputed claim of U.S. Patent 5,569,652 does not cover a use approved by the U.S. Food and Drug Administration.

Bayer argued...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.